Several trials confirmed the superiority of the reversible 1st generation EGFR-TKIs gefitinib and erlotinib, and the irreversible 2nd generation EGFR-TKI afatinib over cytotoxic chemotherapy in terms of response and progression-free survival (PFS) both in pretreated and untreated EGFR-positive NSCLC [3, 4, 5, 6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.